Semnur Pharmaceuticals
2 known investors
Sorrento Therapeutics is a biopharmaceutical company. The available page content is limited to navigation elements and does not describe the company's products or focus in detail.
Biotech
Investors · 2
Non-dilutive funding · 7 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase IISTTR | 2014 | $2M |
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2014 | $586.5K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2014 | $224.8K |
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2014 | $224.6K |
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2012 | $597.8K |
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2011 | $598.7K |
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2010 | $600K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- What does Semnur Pharmaceuticals do?
- Sorrento Therapeutics is a biopharmaceutical company. The available page content is limited to navigation elements and does not describe the company's products or focus in detail.
- Who are Semnur Pharmaceuticals's investors?
- Semnur Pharmaceuticals's investors include Aisling Capital, Canaan Partners.